4SC: Creating a new treatment paradigm for CTCL
Description
There is a lack of effective treatments for Cutaneous T-Cell Lymphoma (CTCL) – in this podcast episode Jason Loveridge, CEO of 4SC, talked to Optimum Strategic Communications’ Eva Haas about the Company’s potential new maintenance therapy Kinselby (resminostat).
4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL).
It has developed Kinselby (resminostat), a novel, oral, maintenance treatment targeting advanced-CTCL, a rare type of non-Hodgkin lymphoma that affects the skin. There are no drugs in development or on the market as maintenance therapy for CTCL.
Kinselby (resminostat) is an orally administered histone deacetylase (HDAC) inhibitor that has produced supportive results in the pivotal RESMAIN trial, where it postponed disease progression in patients – a new treatment paradigm in CTCL.
Hosted on Acast. See acast.com/privacy for more information.
United States
